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Abstract The primary structures of two proteins that comprise 
PA28, an activator of the 20S proteasome, have been determined 
by cDNA cloning and sequencing. These protein subunits, termed 
PA28a and PA28JB, are about 50% identical to one another and 
are highly conserved between rat and human. PA28a and PA28~ 
are homologous to a previously described protein, Ki antigen, 
whose function is unknown. PA28c~, but neither PA28~ nor Ki 
antigen, contains a 'KEKE motif', which has been postulated to 
promote the binding of proteins having this structural feature. 
PA28a and PA2818 were coordinately regulated by y-interferon, 
which greatly induced mRNA levels of both proteins in cultured 
cells. The mRNA level of the Ki antigen also increased in response 
to "y-interferon treatment, but the magnitude of the increase was 
less than that for the PA28s, and the effect was transient. These 
results demonstrate the existence of a new protein family, at least 
two of whose members are involved in proteasome activation. 
They also provide the basis for future structure/function studies 
of PA28 subunits and the determination of their relative physio- 
logical roles in the regulation of proteasome activity. 
Key words': cDNA cloning; Multicatalytic proteinase complex; 
Proteasome; Proteasome activator PA28; ),-Interferon; 
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1. Introduction 
The proteasome is a major intracellular protease involved in 
non-lysosomal mechanisms of protein degradation, including 
the constitutive bulk turnover of cellular proteins [1], the condi- 
tional degradation of specific proteins during temporally con- 
trolled processes uch as the cell cycle [2], and the processing 
of antigens for presentation by class I major histocompatibility 
complexes [1,3]. Proteasome activity is mediated by specific 
regulatory proteins that form proteasome-regulator complexes 
[4]. One such regulator is a large multisubunit protein called 
PA700 [5-8]. PA700 mediates proteasome function in the ubiq- 
uitin-dependent proteolytic pathway. Proteins degraded by this 
*Corresponding author. Fax: (1) (214) 648-8685. 
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pathway must first be modified by covalent conjugation to a 
polyubiquitin chain, which appears to target the substrate to 
the proteasome-PA700 complex by binding to at least one 
PA700 subunit [9]. Degradation of the substrate protein by the 
proteasome-PA700 complex occurs by an ATP-dependent 
mechanism whose biochemical basis is unclear. Although the 
proteasome's best-defined role is in the ubiquitin-dependent 
proteolytic pathway, not all proteasome r gulators activate the 
degradation of ubiquitinated proteins. For example, another 
activator, termed PA28, is a 200,000-dalton protein composed 
of six 28,000-dalton subunits arranged in a ring-shaped struc- 
ture [10-12]. This structure binds to one or both of the pro- 
teasome's terminal rings to form a proteasome-PA28 complex 
[12]. The proteasome-PA28 complex is activated with respect 
to the hydrolysis of small synthetic peptide substrates, but not 
with respect o the degradation of large proteins, regardless of 
their conjugation to polyubiquitin chains [10,11]. Unlike 
PA700's role in the regulation of the proteasome in the well- 
characterized ubiquitin-dependent proteolytic pathway [4], 
PA28's physiological role is unknown. 
PA28 consists of at least two protein subunits of very similar 
molecular weight [11,13]. These subunits, designated in the cur- 
rent report as c~ and fl, represent distinct but homologous gene 
products [13]. Rechsteiner and colleagues recently reported the 
primary structure for one of these proteins and showed that its 
cellular content was increased by treatment of the cells with 
?,-interferon [14]. Because ?,-interferon also alters the expres- 
sion of several proteasome subunits, resulting in changes in 
proteasome composition and possibly in the protease's kinetic 
properties, these findings suggest hat the regulation of PA28 
levels is part of an integrated response of the proteasome sys- 
tem to a common signalling pathway [15-18]. In order to learn 
more about the structure, function, and physiological role of 
PA28, it is essential to determine the primary structure of each 
of its constituent subunits. We report here the complete pri- 
mary structures of the ~ and fl subunits from rat and the fl 
subunit from human. Furthermore, we show that the mRNA 
of each subunit is induced in human cells by ),-interferon. 
2. Materials and methods 
2.1. Construction fcDNA libraries 
Total RNA was extracted from the poly(A) + RNAs of rat hepatoma 
H4TG cells and human hepatoblastoma HepG2 cells by the guanidin- 
0014-5793195/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(95)00492-0 
38 J. Y Ahn et al./FEBS Letters 366 (1995) 37-42 
ium thiocyanate method [19]. Poly(A) + RNA was isolated by 
oligo(dT)30-1atex (Oligotex-dT30; Takara Shuzu). For construction of
cDNA libraries derived from H4TG and HepG2 cells, cDNAs were 
synthesized with a cDNA synthesis kit (Pharmacia LKB Biotechnology 
Inc.) using oligo(dTh5 as a primer for synthesis of the first strand of 
cDNAs. The cDNAs were ligated with an EeoRI adapter containing 
a Notl site and then inserted at the EeoRI site of the 2ZAPII vector 
(Stratagene) for construction of the phage library. 
2.2. Cloning and sequencing of cDNAs 
To isolate a cDNA clone for rat PA28~, a H4TG cell cDNA library 
was screened by utilizing 727 bp of a 32p-labeled PA28ct cDNA previ- 
ously isolated from a bovine brain library (Willy and DeMartino, un- 
published ata). Conditions of hybridization were described previously 
[20]. Twenty positive phages were isolated from about 5 × 105 recombi- 
nants, and the cloned cDNAs were excised in vivo as a pBluescript form 
by using a helper phage, R408. One of the longest clones had an insert 
size of approximately 0.9 kb and was further characterized by nucleo- 
tide sequencing using the dideoxy chain termination method using an 
automatic DNA sequencer (Pharmacia LKB Biotechnology Inc.). 
For isolation of rat and human PA28fl cDNA clones H4TG and 
HepG2 cell cDNA libraries in 2ZAPII were screened using a DNA 
probe generated by bovine liver cDNA templates and PCR-primers 
(5'-CGCATAAGGA(TIC)GA(TIC)GA(A/G)ATGGA-Y and 5'-ACT- 
GCCTCGTCTC(G/T)CTCATGTAGIAGIGC-3'). These oligonucleo- 
tide sequences were based on the published partial amino acid sequence 
of the bovine PA28fl (27.3 kDa PA28) (245). The sense primer corre- 
sponded to the amino acid residues PPKDDEME, whereas the anti- 
sense primer corresponded to the amino acid residues ALVHER- 
DEAV. The reaction was carried out under the conditions as described 
[20], with 30 cycles of denaturation (2 rain at 94°C), annealing (2 rain 
at 50°C), and polymerization (2 rain at 72°C). The amplified products 
were cloned into pBluescript, and sequenced by the dideoxy chain 
termination method. The cloned fragment containing PA28 was excised 
from the plasmid, labeled with [c~-32P]dCTP, and employed as a probe 
for the plaque hybridization screening of cDNA libraries in 2ZAPII. 
Nine positive phages were isolated from about 5 x 105 recombinants 
from the rat H4TG cell cDNA library by screening as described above. 
One of these clones with the longest insert was further characterized by 
sequencing. For isolation of human PA28fl cDNA clones, about 5 x 105 
plaques from the human HepG2 cDNA library were screened, and nine 
positive phages were isolated. Three of these clones were further char- 
acterized by sequencing. These clones, however, were incomplete inthe 
5' untranslated and amino-terminal regions. For isolation of the 5'- 
terminal region of the cDNA, the first strand cDNA, primed with a 
specific primer, was amplified using the adapter primer [21] and another 
specific primer (the complement to nucleotides 321-339) (see Fig. 1C). 
2.3. RNA blot analysis' 
For RNA blot analysis, human renal carcinoma KPK-1 cells were 
cultured as described previously [22]. ),-Interferon was added to culture 
medium at a final concentration f 500 U/ml, and culture was continued 
for 12, 24 and 48 h. Samples of 5 pg of total RNA from the cells were 
separated in agarose gels containing formaldehyde, transferred tonylon 
filters (Hybond N+, Amersham), and hybridized with cDNA probes 
labeled with [cz-3~p]dCTP asdescribed previously [23]. The probes used 
were a rat PA28c~ cDNA fragment (nucleotides 102 510), a PA28fl 
cDNA fragment (nucleotides 243 591) generated by PCR using bovine 
liver cDNA templates, and a human Ki antigen cDNA fragment (nucle- 
otides 469-990) kindly provided by Dr. Y. Nishida of Nagoya Univer- 
sity [24]. fl-Actin cDNA was obtained from Oncor. 
3. Results 
The proteasome activator, PA28, consists of at least two 
distinct but homologous protein subunits with molecular 
weights of approximately 28,000 [13]. In order to further define 
the structural relationships between these subunits, termed 
PA28c~ and PA28fl, we determined their complete primary 
structures by cDNA cloning and sequencing. Using strategies 
described under section 2, a clone for each subunit was identi- 
fied and sequenced from a rat cDNA library. A clone for 
PA28fl was also identified and sequenced from a human cDNA 
library. The nucleotide sequence for each of these three cDNA 
clones and its respective deduced protein is shown in Fig. 1. 
Each sequence contained the entire coding region as well as 
5'-and 3'non-coding regions. The 3'-non-coding region of each 
clone contained a putative polyadenylation signal (AATAAA), 
which was located 12, 13 and 19 nucleotides upstream from the 
poly(A) sequence for rat PA28ct (rPA28~), rat PA28fl 
(rPA28fl), and human PA28fl (hPA28fl), respectively. We con- 
cluded that the ATG sequence assigned nucleotide numbers 
1 3 in each clone is the respective initiation codon because it 
is preceded by a sequence that is similar to the consensus e- 
quence for translation initiation [25], and because this assign- 
ment provides the longest open reading frame for a protein 
whose deduced structure has a molecular weight in good agree- 
ment with that of purified PA28. Comparison of the deduced 
sequences with amino acid sequences determined by automated 
Edman degradation of peptides of two bovine PA28 subunits 
previously reported by Mott et al. [13] indicated that the bovine 
subunit of mass 28,606 daltons is homologous to PA28c~, 
whereas the bovine subunit of mass 27,290 is homologous to 
PA28fl. Sequences of peptides from bovine PA28~ were 93% 
identical (57 of 61 residues) to the corresponding deduced se- 
quence of rat PA28c~; sequences of peptides from bovine PA28fl 
were 87% (101 of 116 residues) and 95% (110 of 116 residues) 
identical to the corresponding deduced sequences of rat and 
human PA28fl, respectively (Fig. 1). 
The rPA28c~ corresponds to a protein of 249 amino acids 
(M r = 8,576) and its sequence is 93% identical to the sequence 
of a 249 amino acid PA28 protein deduced from a human 
cDNA clone recently reported by Rechsteiner and colleagues 
[14] (Fig. 2, Tables 1 and 2). The deduced PA28fl proteins from 
rat and human contained 238 (Mr-26,791)  and 239 
(M r = 27,072) amino acids, respectively (Table 1). The rPA28fl 
and hPA28fl proteins were 89% identical to one another (Fig. 
2, Table 2). These results indicate that each protein has been 
highly conserved between rats and humans. The hPA28c~ and 
hPA28fl proteins were 47% identical to one another, and the 
rPA28~ and rPA28fl proteins were 48% identical to one an- 
other (Table 2). 
The hPA28~ is homologous to a previously described human 
protein, the Ki antigen [24] (Fig. 3). We have not identified the 
Ki antigen protein in our preparations of PA28, and it is un- 
known whether the Ki antigen protein plays any role in the 
regulation of proteasome function. In any case, the sequence 
of the Ki antigen is between 33% and 41% identical to the 
various PA28 sequences (Table 2). 
The primary structures of PA28~ subunits from rat and 
human (Figs. 2 and 3), as well as that from bovine PA28~ (data 
not shown), contain a 'KEKE motif', as described by Realini 
et al. [14]. These regions, from amino acids 70-97, are charac- 
terized by a high content of alternating lysine and glutamic acid 
residues, and by other criteria established for this motif [26]. In 
contrast, neither the PA28fl subunits nor the Ki antigen pro- 
tein, contains this motif and, interestingly, this region of the 
aligned primary structures i one of the most dissimilar among 
the three proteins (Fig. 3). 
Previous work showed that the level of PA28c~ protein was 
greatly increased by treatment of human cells with ),-interferon 
[14,27]. In order to determine whether PA28fl and Ki antigen 
are also regulated by ),-interferon, KPK-1 cells were treated 
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5' -CTCGCGTGCGGCGTTCAC, CCCCGGCI~TGGCC -1 
ATGGCTACACTGAGGGTCCATCCTGAAGCC~TCGATGTGTTTCGTGAGGAC 60 
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A 
5' -~GGGGCTGCTATCCCAGATTCGAGAGCrGGCAA~ -1 
ATGGCCAAGCCTTGTGGGGTTCGCTTGAGTGGAGAAGCCCGTAAACAGGTGGATGCCTTC 60 
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p~ACAAAATCTTTTC~GAGGACTTCCTTTGCACTTTCTTGCCACGGAAAATC 120 
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~,CTGCTTGCCTTGGTTAAGCCAGAAGTCT GGACTCTCAAAGAGAAGTGCATTCTGGTA 360 
A L L A L V K P E V W T L K E K C I L V 120 
ATCACATGGATCCAGCACCTGATCCCCAAGATTGAGGACGCJd~TGATTTTGGGGTGGCA 420 
I T W I Q H L I P K I E D G N D F G V A 140 
ATTCAGGAGAAGGTGC GGAGAGAGTGAATGCTGTCAAGACCAAAGTGGAAGCCTTCCAG 480
I Q E K V L E R V N A V K ~ K V ~ A F O 160 
ACAGCCATCTCCAAGTATTTCTCAGAC,  GTGGGGATGCTGTAGCCAAGGCCT CAAGGAC 540 
._~___~ ~ S K Y F S E R G D A V A K A S K D 180 
ACCCAT GTAATGGATTACCGGGCCTTGGTGCACGAGC AGATGAAGCAGCCTATGGGGCG 600 
T H V M D Y R ~ L V H E R D E A .~... Y G .~... 200 
CTTAGGGCCATGGTGCTGGACCTGAGAGCCTTCTAT GCTGAGCTT CATCACATCATCAGC 660 
L R A M V L D L R A F Y A E L .~.. ~ I I S 220 
AGCAACCTAGAC~TT GTCAACCCAAAGGGTGAAGAAAAGC CATCTATGTACTGAGCA 720 
S N L E K I V N P K G E E K P S M Y * 240 
AAGGATTAGAAGGAAAATAAATGATTTATAC TTT - 3' 754 
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M A K P C G v R L S G E A R K Q v _3. V F 20 
AGGCAGAATCTTTT~GAGGAATTCCTCTACAGAT TCTTGCCACAGAAAATC 120 
1% O N L F O E A E E F L Y R F L P O K ~__ 40 
ATATACCTC~AAT CAGCTC"ETGCAAGAGGACTCCCTCAATGTGGCTGACTTGACTTCCCTC 180 
I Y L N O L L O E D S ~ N V A D L _~ S L 60 
CGGGCCCCACTGGACATCCCCATCCCAGACC TGATGAGA~;AAACA 240 
1% A P L D 1" P I P D P P P K D D E M E T 80 
~TCCCTAAGTGTGGATTTCTCCCTGGGAATGAGAAAGTC 300 
1% K Q E K K E V P K C G F L P G N E K V i00 
CTGTCCCTGCTTGCCCTGGTTAAGCCAGAAGTCTGGACT~TGCATTCTG 360 
L S L L A L V K P E V W T L K E K C I L 120 
GTGATTACATGGATCCAACACCTGATCCCCAAGATTGAAGATGGAAATGATTTTGGGGTA 420 
V I T W I Q H L I P K I E D G N D F G V 140 
GCAATCCAGGAGAAGGTGCTGGAGAGGGTGAATGCCGTCAAGACCAAAGTGGAAGCTTTC 480 
A I Q E K V L E R V N A V K T K V E A ~ 160 
~TTTCCAAGTACTTCTCAGAACGTGGGGATGCTG~CAAG 540 
Q T T I S K Y F S E R G D A V A K A S K 180 
GAGACT CATGTAATGGATTACCGGGCCTTGGTGCATGAGCGAGATGAGGCAGCCTATGGG 600 
E T H V M D Y R A L V H E R D E A .~  ~ G 200 
~TGCTGGACCTGAGGGCCTTCTATGCTGAC~Tx-~'ATCATATCATC 660 
_~ L R A M V L D L R A F Y A E L Y H I I 220 
AGCAGCAACCTGGAGAAAATTGTCACCCCAAAGGG~TCTATGTACTGA 720 
S N L E K I V T P K G E E K P S M Y * 239 
AD, CCGGGACTA~TAAATGATCTATATGTTG TGTGG- 3 ' 763 
C 
Fig, 1. (A) The nucleotide and deduced amino acid sequences of rat PA28a. Nucleotides are numbered starting from A of the translational initiation 
codon ATG. The asterisk (*) shows the termination codon. Continuous underlines show the amino acid sequences corresponding to those obtained 
by Edman degradation of peptides of purified bovine PA28a [13]. The amino acids shown by dotted lines were not identical with those found by 
chemical analysis of bovine PA28a. (B) The nucleotide and deduced amino acid sequences of rat PA28~. (C) The nucleotide and deduced amino acid 
sequences of human PA28~. The cDNA clone isolated from the cDNA library contained nucleotide positions 271-763. The 5'-terminal region was 
determined by the 5'-RACE. 
with ?,-interferon. After varied times of treatment, mRNA lev- 
els for each protein were determined by Northern blot analysis. 
The mRNA levels of both PA28a and PA28fl were greatly 
increased within 12 h and remained elevated for the duration 
of the 48 h exposure of the cells to T-interferon (Fig. 4). The 
mRNA level of the Ki antigen was also induced but by a lesser 
40 
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Fig. 2. Alignment of amino acid sequences ofPA28c~ from rat and human (A), and PA28fl from rat and human (B). Solid lines indicate identity between 
the sequences. 
magnitude than those for the PA28s. Furthermore, the Ki anti- 
gen mRNA level decreased toward control evels during the 48 
h exposure to y-interferon. These results indicate that the two 
PA28 proteins were regulated similarly in response to T-inter- 
feron. 
4. Discussion 
We have determined the primary structures for two protein 
subunits, a and fl, of PA28, an activator of the 20S proteasome. 
Together with a previous report [14], these data allow for the 
comparison of the primary structures of each subunit in two 
species, rat and human. As shown in Table 2, the primary 
Table 1 
Properties of members of the protein family comprised of PA28c~, 
PA28fl, and Ki antigen 
Human AAs Mr pI Rat AAs M r pI 
hPA28c~ 249 28,741 5.71 rPA28c~ 249 28,576 5.70 
hPA28fl 239 27,072 5.33 rPA28,8 238 26,791 5.28 
hKi antigen 254 29,508 5.61 
The indicated properties of PA28~, PA28fl, and Ki antigen were calcu- 
lated from deduced amino acid sequences. The sequences for hPA28~ 
and hKi antigen were taken from [14] and [24], respectively. 
structures of the ~ and fl subunits are 47% and 48% identical 
to each other within each species, whereas the ~ subunits 93% 
identical and the fl subunits are 89% identical between species. 
These data indicate that the divergence of the genes for PA28c~ 
and PA28fl arose by duplication of a common ancestral gene 
before the rat and human species diverged. PA28~ and PA28fl 
are 3341% identical to a third human protein, Ki antigen, 
previously identified as a nuclear protein detected with au- 
toantibodies in sera of patients with systemic lupus erythemato- 
sus [24]. The cellular function of the Ki antigen is unknown and 
we have not detected this protein in our preparations of PA28. 
Rechsteiner and colleagues have expressed PA28~ cDNA in 
Table 2 
Similarities among primary structures of PA28~, PA28fl, and Ki anti- 
gen 
% of amino acid sequence identity 
hPA28c~ hPA28fl hKi rPA28c~ rPA28fl 
antigen 
hPA28c~ 100 
hPA28fl 47 100 
hKi antigen 40 33 100 
rPA28c~ 93 48 41 100 
rPA28fl 47 89 34 48 100 
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Fig. 3. Alignment of amino acid sequences of human PA28~, PA28fl, and Ki antigen. The sequences ofhuman PA28c~ and Ki antigen have been 
taken from published reports [14] and [24], respectively. 
E. coli [14]. The resulting protein activated the proteasome 
similarly to native PA28 purified from cells. Thus, only one of 
the two PA28 subunits is sufficient for proteasome activation. 
Current biochemical data, however, have not clarified whether 
native PA28 is composed of multimers containing both ~ and 
fl subunits (e.g. an ~83 structure), or whether the native protein 
consists of two distinct homohexamers (i.e. separate ~6 and f16 
proteins). Furthermore, it is unclear whether PA28 must form 
hexamers to activate the proteasome orwhether monomers can 
also achieve this activity. 
Despite an amino acid sequence that is similar to those of 
PA28~ and PA28fl, the Ki antigen protein appears to differ 
from PA28 in a number of respects. First, because the Ki 
antigen protein has not been identified in purified preparations 
of PA28 it may be separated from PA28 during purification, 
possibly because it differs from PA28 in any of the physical 
and/or biochemical properties used as the basis for PA28 purl- 
kb 
PA28(z  - 0.9 
PA28[  - 0.9 
K i  ant igen - 2.5 
act in - 2.1 
0 12 24 36 48 
Incubat ion t ime (il) 
Fig. 4. RNA blot analysis from KPK-1 cells after treatment with Z- 
interferon. Samples of total RNA from KPK-1 cells were analyzed with 
each eDNA probe labeled with np as described in section 2. The signals 
generated with the fl-actin probe served as a control. 
fication. Analysis of the distribution of the Ki antigen protein 
with specific antibodies during PA28 purification should deter- 
mine the relative abundance and fractionation of this protein 
when compared to PA28. Second, the Northern blot analysis 
of these proteins howed that the size of the mRNA for the 
c~ and fl PA28s are very similar (0.9 kb), whereas the size of the 
mRNA for the Ki antigen is much larger (2.5 kb). Third, the 
mRNA levels for these three proteins responded ifferently to 
y-interferon treatment (Fig. 4). Functional data regarding the 
ability of the Ki antigen to interact with and activate the pro- 
teasome will provide important insights into the relative struc- 
ture-function relationships of these three proteins. 
The mRNA levels of both PA28(~ and PA28fl were greatly 
induced by treatment of cells with y-interferon. These results 
extend two previous reports which showed that similar treat- 
ment increased cellular protein levels of PA28~ [14,27]. This 
latter effect was originally described by Honor6 et al. for a 
protein they designated 1GUP 1-5111 [27]. These workers also 
deduced the primary structure of the y-interferon-inducible 
IGUP I-5111, but were unaware of its function as a proteasome 
activator. Subsequent cloning and sequencing of hPA28~ es- 
tablished that the two proteins were identical [14]. Although the 
physiological significance of PA28 induction by },-interferon is
unclear, it is interesting to note that 7,-interferon also regulates 
the subunit composition of the proteasome. Thus, }'-interferon 
up-regulates the expression of two proteasome subunits, LMP2 
and LMP7 (both of which are encoded in the major histocom- 
patibility complex), and reciprocally down-regulates two other 
proteasome subunits, X and Y (delta) [15-18]. The resulting 
alteration in proteasome composition has been correlated with 
altered proteasome function including modified kinetic proper- 
ties and substrate specificity [17,28]. These results uggest that 
}'-interferon may promote a coordinated response of the pro- 
teasome system for a specific physiological functions, such as 
the proteasome's proposed role in the production of antigenic 
peptides for presentation by HLA class I molecules. Other 
work has also implicated the proteasome in antigen processing 
because of its role in the ubiquitin-dependent proteolytic path- 
way [1,29]. Although PA28 does not activate the proteasome's 
degradation of ubiquitinated proteins, it is unclear if it might 
42 J. Y Ahn et al./FEBS Letters 366 (1995) 37-42 
play a role in this function when associated with other proteins 
[5]. Alternatively, PA28 may mediate distinct ubiquitin-inde- 
pendent functions of the proteasome. The primary structures 
of both PA28 subunits and the :y-interferon regulation of PA28 
reported here will provide the bases for additional studies to 
determine the physiological role of this activator. 
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